RDD Pharma Inc

TG Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, focused on developing innovative therapies for various diseases, including multiple sclerosis (MS). Their approved product, BRIUMVI, is indicated for the treatment of relapsing forms of MS in adults, offering a new option for patients with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. With a strong emphasis on research and development, TG Therapeutics, Inc. has a robust pipeline of products, including Umbralisib, Ublituximab, TG-1701, and TG-1801. The company's dedication to advancing medical science and improving patient outcomes is evident in their commitment to addressing unmet medical needs and achieving significant milestones in the field of healthcare.Generated from the website

ICC Industries makes raw materials used by pharmaceutical companies to manufacture drugs, and trades basic and specialty chemicals worldwide. The company is an international manufacturer of chemicals, plastics and pharmaceutical products. It also trades and distributes nutritional supplements and food ingredients. The company s subsidiaries include ICC Chemical Corporation, Dover Chemical Corporation, Primex Plastics Corporation, Pace Industries, O Neil Color and Compounding Corporation, Frutarom Industries, Konsyl Pharmaceuticals, and S.C. Azur. Dover Chemical serves the metal-working, coating, adhesive, sealant, plastic, rubber and flame retardant industries. Frutarom Industries is a multinational flavor and fragrance company headquartered in Israel. S.C. Azur is one of the largest paint and lacquer producers in Romania. ICC Industries is headquartered in New York City, and maintains trading and marketing offices in the United States, Africa, Asia, Europe, and the Middle East.

Immunic, Inc. is a biotechnology company based in New York, NY, focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Their mission is to provide high-quality, oral treatment options with comprehensive therapeutic efficacy and outstanding safety for patients suffering from conditions such as multiple sclerosis and celiac disease. With a team dedicated to developing ground-breaking technologies and bringing life-changing therapies to patients, Immunic aims to improve the lives of individuals affected by debilitating diseases by offering new, efficacious, and well-tolerated treatment options. Their drug candidates are designed to combine the convenience of oral delivery with robust efficacy and patient-friendly tolerability, ultimately striving to maximize benefits for patients and create long-term value for stakeholders.Generated from the website